Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Absci Corp.

Headquarters: Vancouver, WA, United States of America
Year Founded: 2011
Status: Public
Industry Sector: HealthTechnology
CEO: Sean McClain
Number Of Employees: 156
Enterprise Value: $288,622,667
PE Ratio: -3.43
Exchange/Ticker 1: NASDAQ:ABSI
Exchange/Ticker 2: N/A
Latest Market Cap: $360,647,808

BioCentury | Oct 5, 2022
Management Tracks

Owkin finds new CBO in Sanofi SVP

Plus CEO Séjourné moves to Aurobac and updates from Quantum, BioHaven and more
BioCentury | Jul 14, 2022
Management Tracks

New CEO at Deerfield-backed Apertura

Plus 10x Genomics hires Wilbur to head commercial, and updates from Immune-Onc, PathAI, Sherlock and more
BioCentury | Mar 25, 2022
Regulation

March 24 Quick Takes: Lilly, Innovent weigh next steps after setback at FDA for PD-1 therapy

Plus: Imfinzi misses and updates from Chugai, YishengBio and more
BioCentury | Jan 8, 2022
Deals

Jan. 7 Quick Takes: AZ adds another amyloidosis mAb via Neurimmune deal

Plus: a16z’s $9B in new funds earmarks cash for bio, and updates from Virtue, AN2, Ultragenx-Regeneron and more
BioCentury | Oct 8, 2021
Product Development

Oct. 7 Quick Takes: Early POC data for Bicycle buoys shares

Plus FDA backs Takeda’s maribavir, RA’s $880M fund and updates from AbbVie, Turning Point, EQRx and more
BioCentury | Jul 23, 2021
Finance

July 22 Quick Takes: Anocca’s $47M B round to support Swedish biotech’s T cell pipeline

Plus: Slingshot, ImmPACT-Kalthera and more
Items per page:
1 - 6 of 6